ACAD (Acadia Pharmaceuticals Inc.) Stock Analysis - Community

Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.70 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

How does the Rallies community trade ACAD?

Rallies community data for ACAD shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.

ACAD Key Metrics

Key financial metrics for ACAD
MetricValue
Price$20.70
Market Cap$3.54B
P/E Ratio9.34
EPS$2.23
Dividend Yield0.00%
52-Week High$28.35
52-Week Low$13.40
Volume12
Avg Volume0
Revenue (TTM)$1.10B
Net Income$375.65M
Gross Margin91.47%

Latest ACAD News

Recent ACAD Insider Trades

  • Kihara James sold 1.33K (~$29.02K) on May 4, 2026.
  • Schneyer Mark C. sold 3.51K (~$76.40K) on May 4, 2026.
  • Schneyer Mark C. sold 2.71K (~$60.14K) on Apr 7, 2026.

ACAD Analyst Consensus

15 analysts cover ACAD: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.77.

Common questions about ACAD

How does the Rallies community trade ACAD?
Rallies community data for ACAD shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
Does Rallies show retail investor data for ACAD?
Rallies shows anonymized community ownership, retail positioning, sentiment, and portfolio context for ACAD when enough community data is available.
Is ACAD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.
ACAD

ACAD